Neurodevelopmental and growth follow-up of the baby exposed to antipsychotics during pregnancy and lactation: a case report

IF 0.5 4区医学 Q4 PHARMACOLOGY & PHARMACY Psychiatry and Clinical Psychopharmacology Pub Date : 2019-06-13 DOI:10.1080/24750573.2019.1627695

Ö. Uygur, H. Uygur

{"title":"Neurodevelopmental and growth follow-up of the baby exposed to antipsychotics during pregnancy and lactation: a case report","authors":"Ö. Uygur, H. Uygur","doi":"10.1080/24750573.2019.1627695","DOIUrl":null,"url":null,"abstract":"ABSTRACT Clozapine is an antipsychotic drug for the treatment-resistant schizophrenia. Although clozapine is superior to other antipsychotics, it is less common in psychiatric prescriptions due to clozaphobia. Little is known about the use of clozapine during pregnancy and lactation, or its effect on the mother, foetus and baby. Pregnancy category of clozapine is considered to be of relatively reliable category B, while it is recommended to be avoided during breastfeeding. Switching from clozapine to other antipsychotics during breastfeeding may lead to psychotic exacerbations. In this case, low dose of clozapine may need to be added to the antipsychotic treatment initiated during breastfeeding. However, data on the safety of combination antipsychotics during breastfeeding are limited. Psychiatrists, obstetricians and pediatricians should closely monitor with team spirit on such cases, thus drug exposure and side effects of infant are minimized while the mother’s mental health is maintained. We aimed to present the growth and neurodevelopmental outcomes of infant exposed to clozapine during pregnancy and exposed to clozapine plus olanzapine during the lactation period.","PeriodicalId":20847,"journal":{"name":"Psychiatry and Clinical Psychopharmacology","volume":"16 1","pages":"744 - 747"},"PeriodicalIF":0.5000,"publicationDate":"2019-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psychiatry and Clinical Psychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/24750573.2019.1627695","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 2

Abstract

ABSTRACT Clozapine is an antipsychotic drug for the treatment-resistant schizophrenia. Although clozapine is superior to other antipsychotics, it is less common in psychiatric prescriptions due to clozaphobia. Little is known about the use of clozapine during pregnancy and lactation, or its effect on the mother, foetus and baby. Pregnancy category of clozapine is considered to be of relatively reliable category B, while it is recommended to be avoided during breastfeeding. Switching from clozapine to other antipsychotics during breastfeeding may lead to psychotic exacerbations. In this case, low dose of clozapine may need to be added to the antipsychotic treatment initiated during breastfeeding. However, data on the safety of combination antipsychotics during breastfeeding are limited. Psychiatrists, obstetricians and pediatricians should closely monitor with team spirit on such cases, thus drug exposure and side effects of infant are minimized while the mother’s mental health is maintained. We aimed to present the growth and neurodevelopmental outcomes of infant exposed to clozapine during pregnancy and exposed to clozapine plus olanzapine during the lactation period.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

妊娠和哺乳期暴露于抗精神病药物的婴儿的神经发育和生长随访:1例报告

氯氮平是一种治疗难治性精神分裂症的抗精神病药物。虽然氯氮平优于其他抗精神病药物，但由于氯氮平恐惧症，它在精神科处方中不太常见。关于孕期和哺乳期氯氮平的使用，以及它对母亲、胎儿和婴儿的影响，我们所知甚少。妊娠期氯氮平被认为是相对可靠的B类，但建议在哺乳期避免使用。在母乳喂养期间从氯氮平切换到其他抗精神病药物可能导致精神病加重。在这种情况下，可能需要在母乳喂养期间开始的抗精神病治疗中添加低剂量的氯氮平。然而，关于母乳喂养期间联合抗精神病药物安全性的数据有限。精神科医生、产科医生和儿科医生应以团队精神密切监测此类病例，从而在保持母亲精神健康的同时，最大限度地减少婴儿的药物接触和副作用。我们的目的是展示婴儿在怀孕期间暴露于氯氮平和在哺乳期暴露于氯氮平加奥氮平的生长和神经发育结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Psychiatry and Clinical Psychopharmacology Medicine-Psychiatry and Mental Health

CiteScore

1.00

自引率

14.30%

发文量

期刊介绍： Psychiatry and Clinical Psychopharmacology aims to reach a national and international audience and will accept submissions from authors worldwide. It gives high priority to original studies of interest to clinicians and scientists in applied and basic neurosciences and related disciplines. Psychiatry and Clinical Psychopharmacology publishes high quality research targeted to specialists, residents and scientists in psychiatry, psychology, neurology, pharmacology, molecular biology, genetics, physiology, neurochemistry, and related sciences.